Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company's products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited. Show More...
-
Website http://www.biotest.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 42.40 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 1.04 1.31 0.94 0.85 0.48 -2.1 -1.17 -0.09 4.58 -0.13 -0.37 Dividends EUR 0.13 0.15 0.17 0.19 0.2 0.02 0.05 0.04 0.04 0.04 Payout Ratio % * 21.1 26.7 19.5 28.0 25.0 8.9 Shares Mil 35.0 35.0 35.0 37.0 40.0 40.0 40.0 40.0 40.0 40.0 42.0 Book Value Per Share * EUR 8.35 9.65 10.15 11.53 12.3 10.06 10.28 8.42 12.76 12.43 11.78 Free Cash Flow Per Share * EUR 0.41 2.7 -0.77 -0.62 -1.75 0.43 -1.2 -3.44 -3.07 -1.87 Return on Assets % 5.84 7.05 4.89 4.03 1.96 -8.31 -4.83 -0.37 17.99 -0.47 -1.37 Financial Leverage (Average) 2.1 1.97 1.85 1.92 2.15 2.34 2.59 2.81 2.11 2.32 2.38 Return on Equity % 13.05 14.3 9.33 7.62 4.0 -18.58 -11.85 -0.99 43.14 -1.05 -3.06 Return on Invested Capital % 16.64 17.04 7.83 6.02 3.62 -9.91 -5.17 0.24 23.7 0.18 -0.41 Interest Coverage 2.08 1.83 7.15 9.1 5.19 -7.64 5.12 -1.92 0.45 0.89 0.4 Current Ratio 2.35 2.5 2.23 4.53 5.27 4.66 3.2 1.79 3.94 4.55 4.27 Quick Ratio 0.89 1.38 0.95 2.63 3.27 2.8 1.72 0.65 2.06 2.04 1.64 Debt/Equity 0.19 0.49 0.68 0.81 0.92 0.83 0.66 0.84 0.87